Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

Summary

This clinical trial will evaluate the safety of chemoimmunotherapy with Naxitamab and COG-type induction chemotherapy in newly-diagnosed patients with high-risk neuroblastoma. We aim to recruit 10 patients over the next 2 years.

Eligibility

Inclusion Criteria:

* Age - 12 months to 21 years at protocol enrollment
* Clinical eligibility criteria:

  1. Newly diagnosed high risk neuroblastoma.
  2. BOTH stage M (INRG - International Neuroblastoma Risk Group) and age ≥547 days.
  3. Patients ≥ 547 days of age who were initially diagnosed with INRG L1 or L2 disease but progress to Stage M without chemotherapy
  4. Patients \< 547 days of age with INRG Stage M or MS disease and patients of any age with INRG L2 with MYCN amplification (v-myc avian myelocytomatosis viral related oncogene)
* Pathology:

  1. Neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis, or
  2. demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines
* Molecular testing:

  1. MYCN testing will be done by FISH (Fluorescence In Situ Hybridization) assessment of the FFPE (Formalin-Fixed Paraffin-Embedded) material submitted from the tumor mass. \> 4-fold increase in MYCN signals as compared to reference signals will qualify as MYCN amplified.
  2. ONCOMINE testing will evaluate ALK (Anaplastic Lymphoma Kinase) mutation
* Timing of patient enrollment

  1. Patients will be enrolled up to 6 weeks from primary diagnosis
  2. Pre-study imaging tests are acceptable up to 3 weeks prior to study enrollment and only if done after any pre-protocol chemotherapy.
* Pre-treatment functional status:

  1. No active bacterial infection without adequate antibiotic therapy
  2. No uncontrolled viral infection - decision will be made after infectious disease consultation
  3. No uncontrolled organ dysfunction:

  i. Renal function based on the Schwartz formula (Schwartz et al. J. Peds, 106:522, 1985). If creatinine level is abnormal chemotherapy treatment will be planned in consultation with Nephrology service. Naxitamab will be initiated if creatinine level is up to 1.2 of normal.

ii. Adequate liver function defined as: -

1. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age,
2. and SGPT (Serum Glutamic Pyruvic Transaminase - ALT) ≤ 10 x ULN\* iii. Adequate cardiac function defined as: -

1\. Shortening fraction of ≥ 27% by echocardiogram, 2. or Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram.

Exclusion Criteria:

* Subjects who have had prior systemic therapy except for localized emergency radiation to sites of life-threatening or function-threatening disease and/or no more than 1 cycle of chemotherapy.
* This will not restrict the emergency regimen at initial diagnosis.
* Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features.
* Patients ≥547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features.
* Patients with known bone marrow failure syndromes.
* Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable.
* Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy.
* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential.
* Lactating females who plan to breastfeed their infants.
* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation.

Conditions2

Interventions1

Related trials

• To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) — Anna Raciborska
• Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma — Giselle Sholler
• Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma — Giselle Sholler
• Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma — Steven DuBois, MD
• Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer — Margaret Gatti-Mays
• Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) — M.D. Anderson Cancer Center

Browse More Trials